Therapy with proton pump inhibitors in patients with type 2 diabetes is independently associated with improved glycometabolic control

Aims Experimental data demonstrated that gastrin has incretin-like stimulating actions on beta-cells, resulting in a promotion of glucose-induced insulin secretion. As proton pump inhibitors (PPIs) consistently increase plasma gastrin levels, a possible effect of this treatment on glucose-insulin homeostasis may be hypothesized. Therefore, the aim of this study was to evaluate the effect of chronic PPIs treatment on glycemic control in patients affected by type 2 diabetes. Methods This is an observational, retrospective study. A total of 548 consecutive patients with type 2 diabetes (mean age +/- A SD: 67.1 +/- A 10.9 years, M/F: 309/239, diabetes duration: 12.4 +/- A 9.8 years) referring to our diabetes outpatient clinics were enrolled; among them, 45 %were treated with PPIs longer than 2 years for preventive/therapeutic purposes. Fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), serum lipids and transaminases were measured by standard laboratory methods. Major cardiovascular events and concomitant medications were recorded in all participants, and daily insulin requirement was calculated in insulin-treated subjects. Results PPIs-treated patients had significantly lower HbA1c (7.1 +/- A 1.07 %-54.1 +/- A 12 vs 7.4 +/- A 1.4 %-57.4 +/- A 8 mmol/mol, p = 0.011) and FPG (127 +/- A 36.9 vs 147.6 +/- A 49.4 mg/dl, p < 0.001) levels than those untreated. These differences increased in patients under insulin therapy and in those with concomitant PPIs + GLP-1-based therapy. The multivariate regression analysis demonstrated that the association between chronic PPIs treatment and HbA1c was independent from possible confounders (p = 0.01). Conclusions PPIs treatment is associated with greater glycemic control in patients with type 2 diabetes, particularly in those on insulin- or GLP-1-based therapy. Our results suggest a role for PPIs in glucose-insulin homeostasis and may open a new scenario for diabetes therapy.